{{header
 | author     = 
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2014
 | month      = 09
 | day        = 18
 | notes      = ''{{USBill|113|S.|2862}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 2
 | title      = Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 ( S. 2862; 113th Congress)
 | bill       = 2862
 | billtype   = s
 | purpose    = To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing, and for other purposes.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|2d Session}}

 
{{Center|S. 2862}}

 
{{Center|IN THE SENATE OF THE UNITED STATES}}

  
{{Center|September 18, 2014}}

 
{{Center| 
[[w:|Mr. Hatch]](for himself and
[[w:|Mr. Whitehouse]]) introduced the following bill; which was read twice and referred to the [[w:United States Senate Committee on Health, Education, Labor, and Pensions|Committee on Health, Education, Labor, and Pensions]] }}

  
{{Center|A BILL}}

 To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing, and for other purposes.   

=Section 1. Short title=

This Act may be cited as the“   Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014   ”. 

=Sec. 2. Scheduling of substances included in new FDA-approved drugs=

   Section 201 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/811 21 U.S.C. 811] )is amended by inserting after subsection (h) the following:

<blockquote> 
:(i) Within 45 days of receiving a recommendation from the [[w:Department of Health and Human Services|Secretary]]to add a drug or substance that has never been marketed in the United States to a schedule under this title, the [[w:United States Department of Justice|Attorney General]]shall, without regard to the findings required by subsection (a) of this section or section 202(b) , issue an interim final rule, under the exception for good cause described in[http://www.law.cornell.edu/uscode/text/5/553 subparagraph (B) ofsection 553(b)of title 5, United States Code], placing the drug or substance into the schedule recommended by the [[w:Department of Health and Human Services|Secretary]]. The interim final rule shall be made immediately effective under[http://www.law.cornell.edu/uscode/text/5/553 section 553(d)(3) of title 5, United States Code]. . 
</blockquote>
 

=Sec. 3. Enhancing new drug development=

   Section 302 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/822 21 U.S.C. 822] )is amended by inserting after subsection (g) the following:

<blockquote> 
:(h) 
::(1) A person who submits an application for registration to manufacture or distribute a controlled substance in accordance with this section may indicate on the registration application that the substance will be used only in connection with clinical trials of a drug in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act .
::(2) When an application for registration to manufacture or distribute a controlled substance includes an indication that the controlled substance will be used only in connection with clinical trials of a drug in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act , the [[w:United States Department of Justice|Attorney General]]shall—
:::(A) make a final decision on the application for registration within 180 days; or
:::(B) provide notice to the applicant in writing of—
::::(i) the outstanding issues that must be resolved in order to reach a final decision on the application; and
::::(ii) the estimated date on which a final decision on the application will be made. . 
</blockquote>
 

=Sec. 4. Registration process under Controlled Substances Act=



==(a) Definitions– ==



===(1) Factors as may be relevant to and consistent with the public health and safety– ===

   Section 303 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/823 21 U.S.C. 823] )is amended by adding at the end the following:

<blockquote> 
:(i) In this section, the phrase“factors as may be relevant to and consistent with the public health and safety”means factors that are relevant to and consistent with the findings contained in section 101 . . 
</blockquote>


===(2) Imminent danger to the public health or safety– ===

   Section 304(d) of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/824 21 U.S.C. 824(d)] )is amended—
:(A) by striking“(d) The Attorney General”and inserting“(d)(1) The [[w:United States Department of Justice|Attorney General]] ”; and
:(B) by adding at the end the following:

<blockquote> 
::(2) In this subsection, the phrase imminent danger to the public health or safety means that, in the absence of an immediate suspension order, controlled substances will continue to be distributed or dispensed by a registrant who knows or should know through fulfilling the obligations of the registrant under this Act, or has reason to believe that—
:::(A) the dispensing is outside the usual course of professional practice;
:::(B) the distribution or dispensing poses a present or foreseeable risk of adverse health consequences or death due to the abuse or misuse of the controlled substances; or
:::(C) the controlled substances will continue to be diverted outside of legitimate distribution channels. . 
</blockquote>


==(b) Opportunity To submit corrective action plan prior to revocation or suspension– ==

   Subsection (c) of section 304 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/824 21 U.S.C. 824] )is amended—
:(1) by striking the last two sentences;
:(2) by striking“(c) Before”and inserting“(c)(1) Before”; and
:(3) by adding at the end the following:

<blockquote> 
::(2) An order to show cause under paragraph (1) shall—
:::(A) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated by the applicant or registrant;
:::(B) direct the applicant or registrant to appear before the [[w:United States Department of Justice|Attorney General]]at a time and place stated in the order, but not less than 30 days after the date of receipt of the order; and
:::(C) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before the date of appearance. 
::(3) Upon review of any corrective action plan submitted by an applicant or registrant pursuant to paragraph (2), the [[w:United States Department of Justice|Attorney General]]shall determine whether denial, revocation or suspension proceedings should be discontinued, or deferred for the purposes of modification, amendment, or clarification to such plan. 
::(4) Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance withsubchapter II ofchapter 5of title 5, United States Code. Such proceedings shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under this title or any other law of the United States. 
::(5) The requirements of this subsection shall not apply to the issuance of an immediate suspension order under subsection (d). . 
</blockquote>
 

=Sec. 5. Report to Congress on effects of law enforcement activities on patient access to medications=



==(a) In general– ==

Not later than 1 year after the date of enactment of this Act, the [[w:Department of Health and Human Services|Secretary of Health and Human Services]], acting through the [[w:Food and Drug Administration|Commissioner of Food and Drugs]]and the [[w:Centers for Disease Control and Prevention|Director of the Centers for Disease Control and Prevention]], and in consultation with the [[w:Drug Enforcement Administration|Administrator of the Drug Enforcement Administration]]and the [[w:Office of National Drug Control Policy|Director of National Drug Control Policy]], shall submit a report to the [[w:United States House Committee on the Judiciary|Committees on the Judiciary of the House of Representatives]], the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce of the House of Representatives]], the [[w:United States Senate Committee on the Judiciary|Committee on the Judiciary of the Senate]], and the [[w:United States Senate Committee on Health, Education, Labor, and Pensions|Committee on Health, Education, Labor and Pensions of the Senate]]identifying—
:(1) obstacles to legitimate patient access to controlled substances;
:(2) issues with diversion of controlled substances; and
:(3) how collaboration between Federal, State, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

==(b) Consultation– ==

The report under subsection (a) shall incorporate feedback and recommendations from the following:
:(1) Patient groups.
:(2) Pharmacies.
:(3) Drug manufacturers.
:(4) Common or contract carriers and warehousemen.
:(5) Hospitals, physicians, and other health care providers.
:(6) State attorneys general.
:(7) Federal, State, local, and tribal law enforcement agencies.
:(8) Health insurance providers and entities that provide pharmacy benefit management services on behalf of a health insurance provider.
:(9) Wholesale drug distributors.  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
